An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: A case series

G. Varkas, K. Thevissen, G. De Brabanter, L. Van Praet, F. Czul-gurdian, H. Cypers, J. De Kock, P. Carron, M. De Vos, P. Hindryckx, J. Arts, I. Vanneuville, P. Schoenaers, B. Claerhout, Maria T Abreu, F. van den Bosch, D. Elewaut

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to a4ß7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the a4ß7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of a4ß7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.

Original languageEnglish (US)
JournalAnnals of the Rheumatic Diseases
DOIs
StateAccepted/In press - Nov 29 2016

Fingerprint

Sacroiliitis
Inflammatory Bowel Diseases
Arthritis
Integrins
Joints
Antibodies, Monoclonal, Humanized
Biological Therapy
Lymphocytes
Vascular Cell Adhesion Molecule-1
Cell Adhesion Molecules
Cohort Studies
Demonstrations
Tumor Necrosis Factor-alpha
Immunoglobulin G
Monoclonal Antibodies
vedolizumab
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Varkas, G., Thevissen, K., De Brabanter, G., Van Praet, L., Czul-gurdian, F., Cypers, H., ... Elewaut, D. (Accepted/In press). An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: A case series. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2016-210233

An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease : A case series. / Varkas, G.; Thevissen, K.; De Brabanter, G.; Van Praet, L.; Czul-gurdian, F.; Cypers, H.; De Kock, J.; Carron, P.; De Vos, M.; Hindryckx, P.; Arts, J.; Vanneuville, I.; Schoenaers, P.; Claerhout, B.; Abreu, Maria T; van den Bosch, F.; Elewaut, D.

In: Annals of the Rheumatic Diseases, 29.11.2016.

Research output: Contribution to journalArticle

Varkas, G, Thevissen, K, De Brabanter, G, Van Praet, L, Czul-gurdian, F, Cypers, H, De Kock, J, Carron, P, De Vos, M, Hindryckx, P, Arts, J, Vanneuville, I, Schoenaers, P, Claerhout, B, Abreu, MT, van den Bosch, F & Elewaut, D 2016, 'An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: A case series', Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2016-210233
Varkas, G. ; Thevissen, K. ; De Brabanter, G. ; Van Praet, L. ; Czul-gurdian, F. ; Cypers, H. ; De Kock, J. ; Carron, P. ; De Vos, M. ; Hindryckx, P. ; Arts, J. ; Vanneuville, I. ; Schoenaers, P. ; Claerhout, B. ; Abreu, Maria T ; van den Bosch, F. ; Elewaut, D. / An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease : A case series. In: Annals of the Rheumatic Diseases. 2016.
@article{55a2f1e9d9164bbb8051bf7b5b479d0f,
title = "An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: A case series",
abstract = "Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to a4{\ss}7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the a4{\ss}7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of a4{\ss}7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.",
author = "G. Varkas and K. Thevissen and {De Brabanter}, G. and {Van Praet}, L. and F. Czul-gurdian and H. Cypers and {De Kock}, J. and P. Carron and {De Vos}, M. and P. Hindryckx and J. Arts and I. Vanneuville and P. Schoenaers and B. Claerhout and Abreu, {Maria T} and {van den Bosch}, F. and D. Elewaut",
year = "2016",
month = "11",
day = "29",
doi = "10.1136/annrheumdis-2016-210233",
language = "English (US)",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease

T2 - A case series

AU - Varkas, G.

AU - Thevissen, K.

AU - De Brabanter, G.

AU - Van Praet, L.

AU - Czul-gurdian, F.

AU - Cypers, H.

AU - De Kock, J.

AU - Carron, P.

AU - De Vos, M.

AU - Hindryckx, P.

AU - Arts, J.

AU - Vanneuville, I.

AU - Schoenaers, P.

AU - Claerhout, B.

AU - Abreu, Maria T

AU - van den Bosch, F.

AU - Elewaut, D.

PY - 2016/11/29

Y1 - 2016/11/29

N2 - Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to a4ß7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the a4ß7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of a4ß7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.

AB - Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to a4ß7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the a4ß7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of a4ß7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.

UR - http://www.scopus.com/inward/record.url?scp=85005963690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005963690&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2016-210233

DO - 10.1136/annrheumdis-2016-210233

M3 - Article

C2 - 27899374

AN - SCOPUS:85005963690

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -